Projected health and economic outcomes over 30 years (mean per 100 000 persons) by strategy
| Early detection | Primary prevention | No intvn | Primary versus ED difference | ED versus no intvn difference | Primary versus no intvn difference | |
| Number of melanomas | ||||||
| All* | 2446 | 1364 | 2419 | −1082 | 27 | −1055 |
| −44.2% | 1.1% | −43.6% | ||||
| In situ melanomas* | 1133 | 601 | 1074 | −531 | 59 | −473 |
| −46.9% | 5.5% | −44.0% | ||||
| Thin melanomas (0≤1 mm)* | 690 | 379 | 676 | −311 | 14 | −298 |
| −45.1% | 2.0% | −44.0% | ||||
| Thick melanomas (>1 mm)* | 623 | 362 | 647 | −261 | −24 | −285 |
| −41.8% | −3.7% | −44.0% | ||||
| Undetected melanomas* | 0 | 21 | 21 | 21 | −21 | 0 |
| 100% | −100% | 0% | ||||
| Number of deaths from melanoma* | 556 | 341 | 567 | −215 | −11 | −226 |
| −38.7% | −1.9% | −39.9% | ||||
| Number of excised keratinocyte cancers* | 65 452 | 47 682 | 64 659 | −17 770 | 793 | −16 977 |
| −27.2% | 1.2% | −26.3% | ||||
| Societal costs (£million) | £493.5 | £386.4 | £406.1 | −£107.1 | £87.4 | −£19.7 |
| −21.7% | 21.5% | −4.9% | ||||
| QALYs | 1 821 195 | 1 822 937 | 1 821 201 | 1742 | −6 | 1736 |
| 0.10% | 0.00% | 0.10% | ||||
| Life years* | 2 635 444 | 2 637 734 | 2 635 396 | 2290 | 49 | 2338 |
| 0.09% | −0.00% | 0.09% |
*Undiscounted.
ED, early detection; intvn, intervention; QALYs, quality-adjusted life years.